Last reviewed 2026-04-20 · How we verify

Vumerity

At a glance

Approved indications

• Relapsing forms of multiple sclerosis

Common side effects

• Flushing
• Abdominal pain
• Diarrhea
• Nausea
• Vomiting
• Dyspepsia
• Eosinophilia
• Elevated hepatic transaminases

Serious adverse events

• Vomiting
• Abdominal pain
• Gastrointestinal events (serious)

Key clinical trials

• A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) (PHASE3)
• Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia (NA)
• A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) (PHASE3)
• A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
• A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
• Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NA)
• Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease (EARLY_PHASE1)
• Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Vumerity CI brief — competitive landscape report
• Vumerity updates RSS · CI watch RSS
• University of Nebraska portfolio CI